[11] Yoda S et al. Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer. Cancer Discov 8, 714–729. [12]王可,李娟,孙建国,等. 间变性淋巴瘤激酶抑制剂不良反应...
[6] Zhao M, Shao T, Shao H, Zhou C, Tang W. Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network me...
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial [J]. Lancet Oncol. 2017;18(7):874-886 [9] Sullivan I, Planchard D. ALK inhibitors in non-sma...
[5]Schneider JL, et al. ALK-positive lung cancer: a moving target. Nat Cancer. 2023 Mar;4(3):330-343. [6]Yoda S, et al. Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer. Cancer Discov. 2018 Jun;8(6):714-729. (来源:...
[1]ALK inhibitors in non-small cell lung cancer: crizotinib and beyond[J].[2]Consensus on diagnosis for ALK positive non-small cell lung cancer in China, the 2013 version.[3]NCCN Guidelines Version 5.2022 Non-Small Cell Lung Cancer.[4]Final Overall Survival Analysis From a Study Comparing...
[17]Yoda S, Lin JJ, Lawrence MS, et al. Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer. Cancer Discov. 2018 Jun;8(6):714-729. doi: 10.1158/2159-8290.CD-17-1256.
[9] Nishio A M , Yoshida B T , Kumagai C T , et al. Brigatinib in Japanese Patients With ALK–Positive Non–Small Cell Lung Cancer Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial[J]. Journal of Thoracic Oncology, 2020, 16...
ALK Inhibitors in Non-Small Cell Lung Cancer: The Latest Evidence and Developments. Ther Adv Med Oncol. 2016;8(1):32-47.Sullivan I, Planchard D. ALK inhibitors in non-small cell lung cancer: the latest evidence and developments. Ther Adv Med Oncol 2016;8: 32-47....
ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. Clin Adv Hematol Oncol. 2014 Jul;12(7):429-39. PMID: 25322323; PMCID: PMC4215402. [2] Bedas Aseel, et al."Efficacy and Safety of ALK Tyrosine Kinase Inhibitors in Elderly Patients with Advanced ALK-Positive Non-Small ...
These patients have benefit from ALK inhibitors and currently, there are three generations of drugs as standard of care. The first generation ALK inhibitor crizotinib is approved in the front line setting for the treatment of advanced NSCLC; unfortunately, these tumors may eventually develop ...